Despite the data of the phase 3 clinical trial, Omalizumab as Therapy in Children and Adults (OUtMATCH), and the US approval, there is currently no indication for the treatment of IgE-mediated food allergies in Europe [10,12,13]. The gene discussed is IGHE; the disease is food allergy.